OptimizeRx Corporation
OPRX
$15.27
-$0.11-0.72%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 109.51M | 104.75M | 94.37M | 92.13M | 88.18M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 109.51M | 104.75M | 94.37M | 92.13M | 88.18M |
| Cost of Revenue | 37.99M | 37.30M | 33.85M | 32.75M | 32.98M |
| Gross Profit | 71.52M | 67.45M | 60.52M | 59.38M | 55.20M |
| SG&A Expenses | 60.42M | 59.46M | 59.46M | 61.27M | 58.56M |
| Depreciation & Amortization | 4.34M | 4.36M | 4.36M | 4.33M | 4.24M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 102.75M | 101.11M | 97.67M | 98.34M | 95.78M |
| Operating Income | 6.76M | 3.64M | -3.30M | -6.22M | -7.60M |
| Income Before Tax | 1.69M | -9.30M | -16.11M | -19.38M | -33.33M |
| Income Tax Expenses | 1.65M | 565.00K | -704.00K | 725.00K | -9.16M |
| Earnings from Continuing Operations | 0.03 | -9.87 | -15.41 | -20.11 | -24.17 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 34.00K | -9.87M | -15.41M | -20.11M | -24.17M |
| EBIT | 6.76M | 3.64M | -3.30M | -6.22M | -7.60M |
| EBITDA | 11.08M | 7.96M | 1.02M | -1.89M | -3.57M |
| EPS Basic | 0.00 | -0.54 | -0.84 | -1.10 | -1.33 |
| Normalized Basic EPS | 0.06 | -0.06 | -0.29 | -0.41 | -0.43 |
| EPS Diluted | 0.00 | -0.54 | -0.84 | -1.10 | -1.34 |
| Normalized Diluted EPS | 0.05 | -0.06 | -0.29 | -0.41 | -0.43 |
| Average Basic Shares Outstanding | 73.98M | 73.72M | 73.47M | 73.17M | 72.53M |
| Average Diluted Shares Outstanding | 75.36M | 74.23M | 73.47M | 73.17M | 72.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |